Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,321 papers from all fields of science
Search
Sign In
Create Free Account
indium In 111 ibritumomab tiuxetan
Known as:
In 111 Ibritumomab Tiuxetan
, In111 ibritumomab tiuxetan
, Indium In-111 Ibritumomab Tiuxetan
Expand
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
IDEC-In2B8/rituximab
IDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Kohei Hanaoka
,
M. Hosono
,
+5 authors
I. Matsumura
EJNMMI Research
2015
Corpus ID: 13268870
BackgroundThe purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of 111In-ibritumomab…
Expand
Review
2010
Review
2010
Handbook of therapeutic antibodies : technologies, emerging developments and approved therapeutics
S. Dübel
2010
Corpus ID: 68720881
Section I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future…
Expand
2009
2009
Japanese phase II study of 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma
K. Tobinai
,
Takashi Watanabe
,
+17 authors
K. Endo
Cancer Science
2009
Corpus ID: 31067630
There is no data about the efficacy and safety of radioimmunotherapy with 90Y‐ibritumomab tiuxetan in patients with relapsed or…
Expand
2008
2008
Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.
S. Baechler
,
R. Hobbs
,
A. Prideaux
,
M. Recordon
,
A. Bischof-Delaloye
,
G. Sgouros
Cancer Biotherapy and Radiopharmaceuticals
2008
Corpus ID: 28034404
UNLABELLED The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in…
Expand
Review
2006
Review
2006
Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
R. Macklis
,
B. Pohlman
International Journal of Radiation Oncology…
2006
Corpus ID: 30181111
Review
2006
Review
2006
Yttrium 90 ibritumomab tiuxetan in lymphoma
M. C. Cheung
,
Adam E. Haynes
,
A. Stevens
,
Ralph M. Meyer
,
Kevin Imrie
,
The members of the hematology disease site group o
Leukemia and Lymphoma
2006
Corpus ID: 6432788
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma…
Expand
2005
2005
Efficacy and Safety of a Single-Course of Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) After/Not Appropriate for Autologous Stem…
O. Weigert
,
C. Schilling
,
+4 authors
M. Dreyling
2005
Corpus ID: 78724419
Radioimmunotherapy (RIT) has demonstrated high clinical efficacy in the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and…
Expand
2004
2004
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase…
F. Morschhauser
,
D. Huglo
,
+11 authors
R. Marcus
2004
Corpus ID: 79151419
Presently, there is no standard second-line regimen for patients (pts) with diffuse large B-cell lymphoma (DLBCL) who cannot…
Expand
Review
2004
Review
2004
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
S. Ansell
,
R. Schilder
,
+7 authors
A. Molina
Clinical Lymphoma
2004
Corpus ID: 35232789
Yttrium 90-labeled ibritumomab tiuxetan is approved for the treatment of patients with relapsed or refractory low-grade…
Expand
Review
2003
Review
2003
Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma
K. Tobinai
International Journal of Clinical Oncology
2003
Corpus ID: 1726213
Among the monoclonal antibodies (mAbs) under clinical development, anti-CD20 mAbs have been most extensively investigated and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE